Can in vitro drug metabolism studies with human tissue replace in vivo animal studies?

Environmental Toxicology and Pharmacology

Volumn 21, Issue 2 SPEC. ISS., 2006, Pages 184-190

  Tingle, M D ^a   Helsby, N A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Drug metabolism; Extrapolation; Liver

Indexed keywords

CYTOCHROME P450;

ANIMAL TESTING ALTERNATIVE; CRYOPRESERVATION; DRUG METABOLISM; DRUG RESEARCH; ENZYME SPECIFICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE CULTURE;

ANIMALIA; INSECTA;

EID: 31544471791     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2005.07.008     Document Type: Article

References (45)

1. M.K. Bayliss, J.A. Bell, W.N. Jenner, G.R. Park, and K. Wilson Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man Xenobiotica 29 1999 253
2. E.F.A. Brandon, C.D. Raap, I. Meijerman, J.H. Beijnen, and J.H.M. Schellens An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons Toxicol. Appl. Pharmacol. 189 2003 233
3. N. Chauret, A. Gauthier, J. Martin, and D.A. Nicoll-Griffith In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse Drug Metab. Dispos. 25 1997 1130
4. R. Gebhardt, J.G. Hengstler, D. Müller, R. Glöckner, P. Buenning, B. Laube, E. Schmelzer, M. Ullrich, D. Utesch, N. Hewitt, M. Ringel, B.R. Hilz, A. Bader, A. Langsch, T. Koose, H.-J. Burger, J. Maas, and F. Oesch New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures Drug Metab. Rev. 35 2003 145
5. G. Gibson, and P. Skett Introduction to Drug Metabolism 1994 Blackie Academic & Professional London
6. M.A. Graham, R.J. Riley, and D.J. Kerr Drug metabolism in carcinogenesis and cancer chemotherapy Pharmacol. Ther. 51 1991 275
7. P.O. Gubbins, R.B. Melchert, S.A. McConnell, A.M. Franks, S.R. Penzak, and B.J. Gurley Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes Pharmacol. 67 2003 195
8. Guidance for Industry, 1997. Drug metabolism/drug interaction studies in the drug development process: studies in vitro. Department of Health and Human Services, U.S. Food and Drug Administration.
9. N.J. Hewitt, K.-U. Buhring, J. Dasenbrock, J. Haunschild, B. Ladstetter, and D. Utesch Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures Drug Metab. Dispos. 29 2001 1042
10. J.B. Houston Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem. Pharmacol. 47 1994 1469
11. J.B. Houston, and K.E. Kenworthy In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model Drug Metab. Dispos. 28 2000 246
12. H.B. Hucker Species differences in drug metabolism Annu. Rev. Pharmacol. 10 1970 99
13. Innovation stagnation: challenge and opportunity on the critical path to new medicinal products, 2004. U.S. Department of Health and Human Services, Food and Drug Administration.
14. H.M. Jones, and J.B. Houston Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations Drug Metab. Dispos. 32 2004 973
15. T. Kennedy Managing the drug discovery/development interface Drug Discov. Today 2 1997 436
16. A. Kern, A. Bader, R. Pichlmayr, and K.-F. Sewing Drug metabolism in hepatocyte sandwich cultures of rats and humans Biochem. Pharmacol. 54 1997 761
17. T. Koppal Advancing in vitro ADME/Tox Drug Discov. Dev. 5 2004 47
18. K.R. Korzekwa, N. Krishnamachary, M. Shou, A. Ogai, R.A. Parise, A.E. Rettie, F.J. Gonzalez, and T.S. Tracy Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites Biochemistry 37 1998 4137
19. B. Laube, S. Winkler, B. Ladstetter, T. Scheller, and L.R. Schwarz Establishment of a novel in vitro system for studying the interaction of xenobiotic metabolism of liver and intestinal flora Arch. Toxicol. 74 2000 379
20. A.P. Li, C. Lu, J.A. Brent, C. Pham, A. Fackett, C.E. Ruegg, and P.M. Silber Cryopreserved human hepatocytes: characterization of drug-metabolizing activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chem. Biol. Interact. 121 1999 17
21. S. Madden, J.L. Maggs, and B.K. Park Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s) Drug Metab. Dispos. 24 1996 469
22. J.L. Maggs, M. Pirmohamed, N.R. Kitteringham, and B.K. Park Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry Drug Metab. Dispos. 25 1997 275
23. J.O. Miners, P.A. Smith, M.J. Sorich, R.A. McKinnon, and P.I. Mackenzie Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches Annu. Rev. Pharmacol. Toxicol. 44 2004 1
24. M. Monshouwer, and K.H. Hoebe Hepatic (dys-) function during inflammation Toxicol. In Vitro 17 2003 681
25. Y. Naritomi, S. Terashita, A. Kagayama, and Y. Sugiyama Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro Drug Metab. Dispos. 31 2003 580
26. Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans Drug Metab. Dispos. 29 2001 1316
27. R.S. Obach Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 27 1999 1350
28. R.S. Obach The prediction of human clearance from hepatic microsomal metabolism data Curr. Opin. Drug Discov. Dev. 4 2001 36
29. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, F. MacIntyre, D.J. Rance, and P. Wastall The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 283 1997 46
30. T. Oinonen, and K.O. Lindros Zonation of hepatic cytochrome P-450 expression and regulation Biochem. J. 329 1998 17
31. O. Pelkonen, P. Myllynen, P. Taavitsainen, A.R. Boobis, P. Watts, B.G. Lake, R.J. Price, A.B. Renwick, M.-J. Gómez-Lechón, J.V. Castell, M. Ingelman-Sundberg, M. Hidestrand, A. Guillouzo, L. Corcos, P.S. Goldfarb, and D.F.V. Lewis Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems Xenobiotica 31 2001 321
32. A. Rane, G.R. Wilkinson, and D.G. Shand Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance J. Pharmacol. Exp. Ther. 200 1977 420
33. R.J. Riley, and J.G. Kenna Cellular models for ADMET predictions and evaluation of drug-drug interactions Curr. Opin. Drug Discov. Dev. 7 2004 86
34. A.D. Rodrigues Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes Biochem. Pharmacol. 57 1999 465
35. C. Rodríguez-Antona, M.T. Donato, A. Boobis, R.J. Edwards, P.S. Watts, J.V. Castell, and M.-J. Gómez-Lechón Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells Xenobiotica 32 2002 505
36. J.S. Salonen, L. Nyman, A.R. Boobis, R.J. Edwards, P. Watts, B.G. Lake, R.J. Price, A.B. Renwick, M.-J. Gomez-Lechon, J.V. Castell, M. Ingelman-Sundberg, M. Hidestrand, A. Guillouzo, L. Corcos, P.S. Goldfarb, D.F.V. Lewis, P. Taavitsainen, and O. Pelkonen Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems Drug Metab. Dispos. 31 2003 1093
37. E.A. Sotaniemi, O. Pelkonen, A.J. Arranto, P. Tapanainen, A. Rautio, and M. Pasanen Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement Pharmacol. Toxicol. 90 2002 155
38. P. Steinberg, T. Fischer, S. Kiulies, K. Biefang, K.-L. Platt, F. Oesch, T. Bottger, C. Bulitta, P. Kempf, and J. Hengstler Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension Drug Metab. Dispos. 27 1999 1415
39. L.B.G. Tee, T. Seddon, A.R. Boobis, and D.S. Davies drug metabolising activity of freshly isolated human hepatocytes Br. J. Clin. Pharmacol. 19 1985 279
40. Y.F. Ueng, T. Kuwabara, Y.J. Chun, and F.P. Guengerich Cooperativity in oxidations catalyzed by cytochrome P450 3A4 Biochemistry 36 1997 370
41. R. Vaclavikova, P. Soucek, L. Svobodova, P. Anzenbacher, P. Simek, F.P. Guengerich, and I. Gut Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs Drug Metab. Dispos. 32 2004 666
42. K. Venkatakrishnan, L.L. Von Moltke, and D.J. Greenblatt Human drug metabolism and the cytochromes P450: application and relevance of in vitro models J. Clin. Pharmacol. 41 2001 1149
43. K.W. Ward, and B.R. Smith A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance Drug Metab. Dispos. 32 2004 603
44. K.W. Ward, and B.R. Smith A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time Drug Metab. Dispos. 32 2004 612
45. R. Zuber, E. Anzenbacherova, and P. Anzenbacher Cytochromes P450 and experimental models of drug metabolism J. Cell. Mol. Med. 6 2002 189